Cost-effectiveness of ivosidenib in patients with previously treated isocitrate dehydrogenase 1 (IDH1)-mutant cholangiocarcinoma: An Italian perspective
Cost-effectiveness of ivosidenib in patients with previously treated isocitrate dehydrogenase 1 (IDH1)-mutant cholangiocarcinoma: An Italian perspective. // Hepatobiliary & Pancreatic Diseases International. – URL: https://www.sciencedirect.com/science/article/pii/S1499387225002553?dgcid=rss_sd_all
Cost-effectiveness of ivosidenib in patients with previously treated isocitrate dehydrogenase 1 (IDH1)-mutant cholangiocarcinoma: An Italian perspective. Hepatobiliary & Pancreatic Diseases International. https://www.sciencedirect.com/science/article/pii/S1499387225002553?dgcid=rss_sd_all
“Cost-effectiveness of ivosidenib in patients with previously treated isocitrate dehydrogenase 1 (IDH1)-mutant cholangiocarcinoma: An Italian perspective.” Hepatobiliary & Pancreatic Diseases International.
@article{article89388,
title = {Cost-effectiveness of ivosidenib in patients with previously treated isocitrate dehydrogenase 1 (IDH1)-mutant cholangiocarcinoma: An Italian perspective},
journal = {Hepatobiliary \& Pancreatic Diseases International},
url = {https://www.sciencedirect.com/science/article/pii/S1499387225002553?dgcid=rss_sd_all}
}